ClinicalTrials.gg
RecruitingNCT06805994NMT Protocol 3Updated Aug 10, 2026

Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment

A Phase 1 interventional study of Nasal Microbiota Transplant (NMT) and Placebo in Staphylococcal Aureus Infection, Microbial Colonization and Pediatric Infection, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 0 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Johns Hopkins University · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
0 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 161 studies in Communicable Diseases with a site in United States — 29 open to participants now, 43 under way, none of them phase 3. Communicable Diseases · United States.

Planned enrollment
37th of 115
175 · median 78
Started
2025
with 7 others
Phase 1
20 of 161
1 open now
Primary completion
2027-09
later than 26 of 40 live
Registered
153rd of 161
by date
Lead sponsor
6 of 161
Johns Hopkins University

Among the 161 studies in Communicable Diseases with a site in United States, this one is the 37th largest by planned enrollment of the 115 interventional ones that give a count, is one of 8 that started in 2025, is one of 20 in phase 1, reaches primary completion later than 26 of the 40 other live ones, and was the 153rd registered.

Communicable Diseases

628 studies on the registry are indexed under Communicable Diseases; 129 are open to participants now.

Browse Communicable Diseases studies →

Open to participants now

29 of the 161 studies in Communicable Diseases with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.

This study: 0 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Communicable Diseases with a site in United States, or all of them as a file.
02

Study summary

This protocol aims to evaluate how NMT affects pediatric nasal microbiome diversity following intranasal mupirocin treatment

Read the detailed description

This parent-to-child NMT study will test the effect of an anterior nares, or nasal, microbiota transplant (NMT) on seeding, engraftment, and diversity of the neonatal microbiome following nasal decolonization for S. aureus. Infants admitted to the Johns Hopkins Neonatal Intensive Care Unit (NICU) will be screened and parents will be approached for enrollment in the study. After consent and baseline screening of parents and infants, eligible infants will undergo an NMT.

03

Conditions studied

  • Staphylococcal Aureus Infection
  • Microbial Colonization
  • Pediatric Infection
  • S. Aureus Colonization
  • Microbial Transplant

Keywords

  • microbiome
  • s. aureus
  • staph
04

Who can participate

Ages eligible
0 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Child:

Inclusion criteria

  1. Child has had a prior nasal surveillance culture grow S. aurues
  2. Child is \<18 years of age
  3. Child completed treatment with intranasal mupirocin for S. aureus nasal colonization as part of routine clinical care two or more days before the planned transplant
  4. Child has anticipated hospital length of stay >3 days after completing intranasal mupirocin treatment
  5. Infant >25 weeks gestation unless >2 months chronological age

Exclusion criteria

  1. Child is a ward of the State
  2. Child with a diagnosis of immunodeficiency or antenatal suspicion for immunodeficiency (e.g., sibling with known immunodeficiency, genetic syndrome with known associated immunodeficiency)
  3. Child cannot have nasal swabs collected (due to anatomic or other clinical intervention, including nasal packing)

Donor:

Inclusion criteria

  1. Donor is able to provide
  2. Donor has a relationship with the child outside of the hospital setting (i.e., not an ICU caregiver)

Exclusion criteria

  1. Donor had positive COVID-19 test in prior 21 days
  2. Donor with signs or symptoms of respiratory illness (e.g. runny nose, congestion, fever, cough)
  3. Donor has been in close contact with someone in the last 7 days who had a respiratory viral infection (e.g., cold, flu)
  4. Donor tests positive on baseline screening test for S. aureus nasal colonization.
  5. Donor tests positive on baseline screening test for a respiratory pathogen.
  6. Donor is not able to provide written informed consent
  7. Donor is not able to be present at the bedside at the time of intervention.
  8. Donor has history of chronic sinusitis, cystic fibrosis, or an infection with a multi-drug resistant organism.
  9. Inability or unwillingness to complete the Donor questionnaire or a positive response to any question on the Donor questionnaire.
  10. Donor has smoked within the last month
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
175 participants (estimated)

Study arms

  • Experimental
    Single NMT

    Swab parent nares then insert swab directly into child nares once.

    Biological: Nasal Microbiota Transplant (NMT)

  • Experimental
    Repeat NMT

    Swab parents nares then insert swab directly into child nares multiple times.

    Biological: Nasal Microbiota Transplant (NMT)

  • Placebo comparator
    Placebo

    Insert a sterile swab into child nares.

    Biological: Placebo

Interventions

  • BiologicalNasal Microbiota Transplant (NMT)

    nasal microbiota transplant

  • BiologicalPlacebo

    Placebo sterile swab

06

What researchers measure

Primary outcomes

  1. Pediatric nasal microbiome diversity after parent-to-child NMT.

    This outcome will be determined by analysis of periodic surveillance swabs collected after intervention.

    Time frame: Day 2, 4, 7, 10, 14 days post-intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

Of 25 phase 1 interventional studies under Communicable Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2025
First posted
Feb 3, 2025
StartActual
Aug 27, 2025
Primary completionEst.
Sep 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06805994
Responsible party
Sponsor
First posted
Feb 3, 2025
Start date
Aug 27, 2025
Primary completion
Sep 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Aug 10, 2026

Study contacts

Danielle Koontz, Research Manager
Contact
dkoontz1@jhmi.edu
4432879040
Slade Decker, Senior Research Coordinator
Contact
sdecker9@jhmi.edu
4109550405
Aaron M Milstone, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion